Tempest Therapeutics reported third quarter 2026 financial results and provided a business update on its in vivo CAR-T pipeline, including the lead candidate TPST-4903. During the quarter, the company exercised its option for an exclusive license to Senlang's CD7-targeted platform and secured access to capital through a $50 million equity line of credit and a $2.5 million private placement.
“The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases.”
Matt Angel, Ph.D., president and chief executive officer of Tempest
“We made important strides in expanding our pipeline and strengthening our position in the rapidly evolving in vivo CAR-T landscape through our strategic collaboration with Senlang by obtaining exclusive license rights to our clinical-stage BCMA/GPRC5D in vivo CAR-T candidate TPST-4903, while securing access to additional capital to support our development priorities.”
Matt Angel, Ph.D., president and chief executive officer of Tempest
Tempest Therapeutics filed its Q3 2026 10-Q reporting 19,995,358 shares of common stock outstanding as of November 13, 2026. The company is focused on advancing its clinical-stage programs, including TPST-4003 and TPST-2003, while addressing substantial risks regarding its ability to continue as a going concern and maintain Nasdaq listing compliance.
Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
Tempest Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders elected two Class II directors and ratified Ernst & Young LLP as the independent auditor. Stockholders also approved two key financing-related proposals under Nasdaq rules, including the potential issuance of shares to Lincoln Park Capital Fund and shares issuable upon the exercise of warrants from a September 2026 private placement.